English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, November 24, 2017
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
エーザイ、第71回米国てんかん学会議にてペランパネルおよびルフィナミドに関する最新データを発表
Monday, November 20, 2017
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
Friday, November 17, 2017
エーザイ、ドイツにおいて公的医療保険中央連合会との合意に基づき、抗てんかん剤「Fycompa(R)」の販売を12月に再開
Monday, November 6, 2017
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
エーザイ、第10回アルツハイマー病臨床試験会議(CTAD)にてaducanumabの臨床第Ib相試験の長期継続投与に関する最新データを発表
Tuesday, October 31, 2017
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China
エーザイ、第10回アルツハイマー病臨床試験会議(CTAD)において、最新の知見を発表
エーザイ: 中国で抗がん剤「レンバチニブ」の肝細胞がんに係る適応による新薬承認申請が受理

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575